Nuvalent, Inc.

NUVL · Nasdaq · SIC 2834: Pharmaceutical Preparations
88
SEC Filings

Business Summary

PART I Overview We are a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. We leverage our teams deep expertise in chemistry and structure-based drug design to develop innovative small molecules that are designed with the aim to overcome the limitations of existing therapies for clinically proven kinase targets. Limitations faced by currently available kinase inhibitors can include (i) kinase resistance, or the emergence of new mu...

Next Earnings

Q2 FY2026 — expected 2026-09-16

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionNUVLdiscussed_in_filing Cybersecurity
topic_mentionNUVLdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-262025-12-310001193125-26-073317EDGAR113K words
2025-02-272024-12-310000950170-25-028328EDGAR—
2024-02-272023-12-310000950170-24-020607EDGAR—
2023-03-162022-12-310000950170-23-008284EDGAR—
2022-03-292021-12-310001193125-22-087401EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-10-302025-09-300001193125-25-257357EDGAR75K words
2025-08-072025-06-300000950170-25-104532EDGAR—
2025-05-082025-03-310000950170-25-066401EDGAR—
2024-11-122024-09-300000950170-24-124518EDGAR—
2024-08-082024-06-300000950170-24-093285EDGAR—
2024-05-092024-03-310000950170-24-056232EDGAR—
2023-11-142023-09-300000950170-23-063341EDGAR—
2023-08-102023-06-300000950170-23-040937EDGAR—
2023-05-112023-03-310000950170-23-020807EDGAR—
2022-11-102022-09-300000950170-22-024138EDGAR—
2022-08-102022-06-300001193125-22-216780EDGAR—
2022-05-122022-03-310001193125-22-148022EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-02-260001193125-26-073304EDGAR2K words
2026-01-140001193125-26-012243EDGAR—
2025-12-160001193125-25-320150EDGAR—
2025-12-100001193125-25-314165EDGAR—
2025-11-200001193125-25-288770EDGAR—
2025-11-170001193125-25-283893EDGAR—
2025-10-300001193125-25-257347EDGAR—
2025-09-220001193125-25-209934EDGAR—
2025-08-070000950170-25-104531EDGAR—
2025-07-210000950170-25-097069EDGAR—

88 total filings indexed. 61 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001861560
TickerNUVL
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 8758c00f56c2e414a08af52010d6b273fd738c5b6bc8e8827658a2a7180d6da1
parent: d6e55a90bd67c1be9486c3cdd16bfb9bae03a46ec9eaf70e921ed1603e26d636
content hash: 68374235fd6322ee3cc0915d9fde6e337a366fa00926865c3b581606dee3951b
signed: 2026-04-13T04:46:37.191Z
sources: 17 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf